The present study aims to find out the possible protective effect of abscisic acid (ABA) on the development of diabetic cardiomyopathy (DCM) in type 2 diabetic rats. Materials and methods:
INTRODUCTION
Diabetes mellitus (DM) is a global metabolic disease that continues to be a health problem in the developed as well as developing nations. Epidemiological studies predict that it will affect nearly 400 million people by 2030 [1] .
Cardiovascular complications are the most common cause of morbidity and mortality in patients with diabetes [2] . Both type1 and type2 diabetes mellitus promoted cardiac dysfunction; a condition described as diabetic cardiomyopathy (DCM), either directly or indirectly. DCM could be induced directly by upregulation of calpain-1 specifically in mitochondria that induce the cleavage of ATP synthase, increase in superoxide generation and apoptosis in cardiomyocytes [3] . In addition, increased formation of myocardial advanced glycation end-products (AGEs) that associated with hyperglycemia has also been reported to promote collagen accumulation and fibrosis in the cardiac tissue [4] . Also, DCM may be promoted indirectly through premature atherosclerosis [5] . The risk incidence of developing heart failure increases in DM regardless of hypertension, obesity, hyperlipidemia or underlying coronary heart disease [6] . In the early stages, diabetic cardiomyopathy may present with diastolic dysfunction and subsequently proceed to systolic dysfunction [7] . The pathogenesis of diabetic cardiomyopathy is incompletely understood, and limited treatment options exist.
2-Cis, 4-trans-abscisic acid (ABA) is a plant hormone that regulates important physiologic functions, such as the response to abiotic stress (water and nutrient availability, UV irradiation) [8] . It is also present in mammalian plasma, and several cell types like human granulocytes, mesenchymal stem cell and pancreatic B cells have been shown to produce it [9] . Bruzzone et al. (2007) found that ABA released from human granulocytes stimulates phagocytosis, cell migration, and production of reactive oxygen species indicating that ABA should be considered as a new pro-inflammatory cytokine in humans [10, 11] . Also, ABA was found to decrease macrophage accumulation in white adipose tissue of obese diabetic mice [12, 13] . Activated platelets or quartz particles stimulate ABA release from monocytes/macrophages which in turn stimulates release of cytokines and prostaglandin E2 in an autocrine manner [14, 15] . IL-8 induces human mesenchymal stem cells to release ABA, which stimulates the release of growth factors from these cells and colony growth from human hemopoietic progenitors [16, 17] .
ABA is also suggested to be involved in the regulation of glucose metabolism in humans.
Plasma ABA (ABAp) concentration increases in humans after a glucose overload, indicating that it is an endogenous hormone [9] . This glucose overload stimulates β-pancreatic cells release of ABA, which in turn stimulates insulin release [12] .
In vitro, ABA stimulates glucose uptake in murine cells, independent of insulin, by increasing the expression and membrane translocation of the glucose transporter (GLUT)-4 in skeletal muscle [2] . Most recently, Ameri et al. [16] noticed that an impairment of the hyperglycemia-induced increase in ABAp was observed in subjects with type 2 diabetes mellitus (T2DM) and with gestational diabetes mellitus (GDM). They also observed an interesting finding in women with GDM one month after child birth; ABAp either fasting or in response to glucose is restored to normal, along with glucose tolerance. These in vivo results strongly suggest a beneficial effect of elevated ABAp on glycemic control in humans.
Abscisic acid is structurally similar to thiazolidinediones (TZDs) which are PPAR-γ agonists, have been shown to be very effective in improving systemic insulin sensitivity. It is found that ABA could be used as a nutritional supplement to combat T2DM and obesity-related inflammation [17] . No side effects were observed in ABA-fed mice, such as excess weight gain and fluid retention, which are commonly observed with TZDs [18] . Moreover, an in vitro study of Vigliarolo et al. [19] suggested a role for endogenous ABA in the protection against oxygen depletion in cardiomyocytes, by stimulating NO production and glucose uptake. So, we aim in this study to find out the role of abscisic acid in metabolic control of T2DM rats and its possible protective effect on the development of diabetic cardiomyopathy.
Materials and Methods:
Fifty male Sprague-Dawley rats (220-240 g) were procured at our Medical Experimental Research Center of Mansoura University, Egypt and housed in an air-conditioned room at a temperature of 25±2 ºC and relative humidity of 45% to 55% under 12-h light: 12-h dark cycle. The animals had free access to food pellets except when starvation was required. Water was provided ad libitum. The protocol of this research followed Abscisic acid (1 mg/kg/day) [20] and pioglitazone (10 mg/kg/day) [20] were administered by oral gavage throughout the experimental period. ECG recording and body weight (BW) were measured just before induction of diabetes and at the end of study periods.
Overnight fasted rats were anesthetized using urethane (1 g/kg, ip sampling. The rats with plasma glucose ≥300 mg/ dl were considered diabetic and selected for our study.
Assessment of electrocardiography (ECG)
ECG was recorded twice for each rat, one QTc were calculated according to the following formula:
Where f is the normalization factor according to the basal RR duration in rats, which is 150 ms [24] .
Measurement of serum parameters
Serum levels of glucose (GL) concentration (mg/dl) was measured by a glucose oxidase method and fasting insulin (FI) (μU/ml) was estimated using radio immune assay (RIA) kit (Sigma -Aldrich, St Louis, MO, USA).
HOMA-IR was used to assess insulin sensitivity [25] .
Serum levels of total cholesterol (TC), triglycerides (TG), and high-density lipoprotein (HDL) cholesterol were assayed according to the methods of Allain et al [26] , Fossati and Prencipe [27] and Burstein et al [28] using diagnostic kits purchased from Analyticon, Biotechnologies AG, (Germany). 
Assessment of caspase-3 and caspase9 activity in cardiac tissues
All procedures were performed at 4°C. The heart samples were lysed by 30 strokes using a Konetes homogenizer at a ratio of 100 mg tissue/1 ml lysis buffer [ 50 mM Tris-HCl (pH 7.4), 2 mM EDTA, 2 mM EGTA, 150 mM NaCl, 1 mM PMSF, 10 μg/ml leupeptin, 1 mM sodium orthovanadate, 1%
Nonidet P40, and 0.3% sodium deoxycholate].
These homogenates were centrifuged at 100,000 g for 1 h. The supernatant was stored at -70°C for biochemical assays of caspase-3 and 9 activities using colorimetric assay kits; the procedures were 
Histopathological studies
The second portion of isolated heart were preserved in 10% formalin for 24 h. Specimens were cut in section of 3-5 μm in thickness to be stained with hematoxyline and eosin (H&E) stain in order to examine the morphological changes.
Additionally, heart sections were stained with 
Statistical analysis
Expression of the results were shown as mean ± SD of the rats in each group. The results were statistically analyzed using One-way ANOVA followed by post-hoc test to evaluate the significance between the different investigated groups using SPSS version 16 (Chicago, IL, USA).
Values with P < 0.05 were statistically considered significant.
RESULTS
The results presented in table (2) revealed a significant reduction in the body weights of diabetic group as compared to control group. As regarding HW/BW ratio in diabetic rats, there was significant increase in this ratio as compared to control rats with significant reduction in all treated groups when compared to the diabetic one. Table   ( 2) also showed significant increase in serum glucose and HOMA-IR with significant reduction in serum insulin levels in diabetic group. However, treated groups showed significant improvement in these measured parameters especially, in ABA and combined treated groups.
Regarding to the lipid profile parameters, figure (1) showed significant elevation in serum levels of TG, TC, LDL, and VLDL with reduction in HDL in diabetic rats as compared to control.
These parameters were significantly improved in treated rats especially in the combined treated group. To explore the impact of diabetes-induced hyperlipidemia and protective effect of ABA on the heart, the cardiovascular risk indices were calculated as shown in figure (2) . Diabetic rats showed significant increase in both cardiac indices when compared with the control rats. However, ABA supplemented rats for 16 weeks exhibited marked improvement in these recorded indices. Table ( 3) showed significant elevation in serum troponin I, CK-MB, LDH, IL-1β and TNF-α levels of diabetic rats as compared to control ones.
While, ABA treated groups showed significant decrease in their serum levels when compared to the diabetic rats. 
